Rani Therapeutics Holdings, Inc. (RANI) Stock Price, Financials & Summary

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$0.64

From 52W high−77.18%

Volume455786.00

Market cap$75.06M

P/E (TTM)—

P/S (TTM)15.4x

Div yield—

Key dataOct 19, 2026

Open

$0.64

From 52W high

−77.18%

Volume

455786.00

Market cap

$75.06M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−1.1x

P/E (TTM)

—

RSI (14)

31.7

MomentumView details →

1D Return

+1.51%

YTD Return

−52.39%

SummaryUpdated Jun 1, 2026

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) is a clinical-stage biotherapeutics company founded in 2012 and headquartered in San Jose, California. The company went public in July 2021 and has developed a revolutionary oral drug delivery platform called the RaniPill capsule, which aims to transform how patients receive biologic medications by replacing injections with oral pills. Rani focuses on converting injectable biologics into orally administered treatments across multiple therapeutic areas including immunology, endocrinology, and obesity management.

Ask drillr about Rani Therapeutics Holdings, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−1.1x

EV/Sales

7.0x

P/S (TTM)

15.4x

P/B (TTM)

1.9x

ProfitabilityView details →

Gross Margin

96.70%

Net Margin

−618.02%

EBITDA Margin

−655.10%

ROE (TTM)

−76.82%

ROA (TTM)

−49.54%

Asset Turnover

0.09x

GrowthView details →

Revenue YoY

+306.42%

EPS YoY

+70.43%

FCF YoY

+34.92%

Revenue CAGR 3Y

+58.85%

EPS CAGR 3Y

+57.14%

EBITDA YoY

+32.18%

MomentumView details →

1D Return

+1.51%

YTD Return

−52.39%

1Y Return

−71.44%

RSI (14)

31.7

vs 50D SMA

−20.20%

vs 200D SMA

−33.63%

Capital & dividendView details →

Debt/Equity

0.09x

Current Ratio

5.31x

Quick Ratio

5.31x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.04

EPS Surprise

20.00%

Beats (12Q)

5/12

Next Q EPS Est

−$0.05

Avg Surprise (4Q)

−28.33%

Rev Surprise

84.76%

Financials snapshotView financials →

Revenue (TTM)

4.88M

Net Income (TTM)

−30.14M

Op. CF (TTM)

−20.29M

Next earningsNov 5, 2026 →

Latest newsMore news →

Rani Therapeutics announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing.67d ago

Rani Therapeutics reported financial results for the second quarter ended June 30, 2026.67d ago

Similar companies

ProMIS Neurosciences, Inc.PMN OKYO Pharma LimitedOKYO Nutriband Inc.NTRB China Regenerative Medicine International Limited08158.HK Acrivon Therapeutics, Inc. Common StockACRV Neonc Technologies Holdings, Inc.NTHI Find similar companies →

Latest newsMore news →

Rani Therapeutics announced positive initial Phase 1a data for RT-114, with oral bioavailability achieving systemic exposure greater than 150% relative to matched subcutaneous dosing.67d ago Rani Therapeutics reported financial results for the second quarter ended June 30, 2026.67d ago